Last reviewed · How we verify
Benidipine Hydrochloride
Calcium channel blocker
Calcium channel blocker Used for Hypertension.
At a glance
| Generic name | Benidipine Hydrochloride |
|---|---|
| Sponsor | The Society of Prevention and Awareness of Cardiovascular Diseases |
| Drug class | Calcium channel blocker |
| Target | L-type calcium channels |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
Benidipine hydrochloride is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions into smooth muscle cells, leading to vasodilation and a reduction in blood pressure.
Approved indications
- Hypertension
Common side effects
- Dizziness
- Headache
- Fatigue
Key clinical trials
- Benidipine in Hypertensive and/or Chronic Coronary Syndrome Patients
- Benidipine and Hydrochlorothiazide in Fosinopril Treated Chronic Kidney Disease Patients With Hypertension (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: